Guideline 10.9 — Neonatal Thrombosis

BEDSIDE ACTION BOX

Neonates are the paediatric age group at highest risk of thrombosis — most are catheter-related (umbilical/central venous or arterial lines).
Suspect thrombosis with a malfunctioning/blocked line, limb discoloration or swelling, a poorly perfused limb (arterial), persistent thrombocytopenia, or organ dysfunction; classic renal vein thrombosis = the triad of a flank mass, haematuria, and thrombocytopenia.
Confirm with Doppler ultrasound (first-line); echocardiography for intracardiac/great-vessel thrombus.
Assess the line: if it is thrombosed/no longer needed, remove or replace it (individualize timing to avoid embolization).
Balance anticoagulation against bleeding risk individually with hematology — small, stable, asymptomatic thrombi may be monitored; larger/limb- or organ-threatening thrombi need anticoagulation (and rarely thrombolysis).

1. Overview

Overview

Neonatal thrombosis is uncommon but the neonatal period carries the highest incidence in childhood, driven overwhelmingly by indwelling vascular catheters plus the physiological differences of the neonatal hemostatic system and frequent critical illness. Management is individualized and specialist-led because the neonate sits between a real thrombotic risk and a heightened bleeding risk (especially intraventricular hemorrhage in preterm infants), so the decision to anticoagulate weighs the size, site, and threat of the thrombus against bleeding hazard.

Why This Topic Matters

Thrombosis can threaten limbs and organs (kidney, gut, brain) and life, yet over-aggressive anticoagulation/thrombolysis in a preterm infant can cause catastrophic hemorrhage. Recognizing, imaging, and individualizing treatment with hematology is essential.

2. Who This Guideline Applies To

Scope

Neonates with catheter-related or spontaneous venous/arterial thrombosis, including renal vein thrombosis and intracardiac thrombus.
Infants with vascular catheters at risk of thrombosis.
Cross-references: the bleeding neonate (10.3), platelet disorders (10.4), stroke/CSVT (9.5), PN/line care (7.2), and polycythemia (10.8).

3. Key Definitions

Term	Definition
CRT	Catheter-related thrombosis — the commonest neonatal thrombosis.
Renal vein thrombosis (RVT)	The commonest non-catheter venous thrombosis; classic triad of flank mass, haematuria, thrombocytopenia.
Anticoagulation	Unfractionated heparin or low-molecular-weight heparin (LMWH) to prevent propagation.
Thrombolysis	Clot-dissolving therapy (e.g., tPA) — reserved for limb-/organ-/life-threatening thrombosis (high bleeding risk).

4. Types

Type	Note
Catheter-related venous	UVC/central line; commonest; may involve great veins/right atrium.
Catheter-related arterial	UAC/peripheral arterial line; limb ischemia risk.
Renal vein thrombosis	Commonest spontaneous venous; flank mass, haematuria, thrombocytopenia.
Intracardiac / great-vessel	Often catheter-tip related; echocardiography.
Cerebral sinovenous thrombosis	See 9.5; may need anticoagulation (specialist).

5. Risk Factors

Contributors

Vascular catheters (the dominant factor) — UVC/UAC/central lines.
Critical illness: sepsis, dehydration, polycythemia, asphyxia, congenital heart disease, infant of a diabetic mother.
Maternal/inherited: severe inherited thrombophilia (rare; test only in selected cases), antiphospholipid antibodies.

6. Presentation

Recognize the Patterns

Line dysfunction (won't flush/aspirate); limb swelling/discoloration (venous) or a pale, cold, pulseless limb (arterial ischemia — urgent).
Persistent/unexplained thrombocytopenia; superior vena cava obstruction (head/neck swelling); chylothorax.
Organ-specific: renal vein thrombosis (flank mass, haematuria, thrombocytopenia); portal vein thrombosis (later portal hypertension); intracardiac thrombus.

7. Management Algorithm

Suspect & image

Line dysfunction/limb signs/thrombocytopenia/organ signs → Doppler ultrasound (echo for intracardiac/great-vessel).

Assess the line & the threat

Remove/replace thrombosed or unnecessary lines (timing individualized); assess whether the thrombus threatens a limb, organ, or life.

Involve hematology; weigh bleeding risk

Balance anticoagulation benefit against bleeding hazard (IVH in preterm) — decision is individualized and specialist-led.

Choose the strategy

Small/stable/asymptomatic → often monitor with serial imaging. Significant/propagating → anticoagulate (UFH or LMWH). Limb-/organ-/life-threatening → consider thrombolysis (high risk) per specialist.

Monitor & reassess

Serial imaging for resolution/propagation; monitor for bleeding and anticoagulant levels; adjust with hematology.

⚠ Do-not-miss

Arterial limb ischemia (urgent); intracardiac thrombus/embolization; anticoagulant-related IVH/bleeding; and renal vein thrombosis.

8. Treatment Options (Specialist-Led — Verify Doses)

Option	When	Cautions
Watchful monitoring	Small, stable, asymptomatic thrombi	Serial imaging; treat if propagating.
Anticoagulation (UFH or LMWH)	Significant/propagating thrombosis	Bleeding risk (IVH); monitor levels; adjust for renal function/prematurity.
Thrombolysis (e.g., tPA)	Limb-/organ-/life-threatening	Major hemorrhage risk; specialist decision; contraindicated with recent IVH/surgery.
Line removal/replacement	Thrombosed/unnecessary catheters	Timing individualized (embolization risk).

⚠ Verify

Anticoagulant/thrombolytic agents, doses, monitoring (anti-Xa/APTT), and contraindications must follow the Neonatal Formulary and hematology advice; screen for bleeding (cranial ultrasound) before anticoagulation in preterm infants. Section 8+ below gives Baylor Ed. 33's dosing, titration and duration rules — confirm against local policy before use.

8+. Risk Stratification, Dosing and Duration (Baylor Ed. 33)

How urgent is this thrombus?

Low risk: non-occlusive, asymptomatic venous thrombus (catheter-related, portal vein) or a chronic organized venous thrombus. Watch and wait until resolution — re-image in 3–7 days, then at intervals of 1–4 weeks based on what you see.
Moderate risk: any symptomatic or acute occlusive venous thrombus without ischaemia or organ failure; bilateral renal vein thrombosis; a thrombus propagating on serial imaging; or one extending into a central vein (SVC, IVC). Consult haematology, send baseline coagulation studies, image closely, and if catheter-related consider line removal weighed against the need for access.
High risk: any arterial thrombus; any thrombus causing limb ischaemia or organ injury (renal impairment, cardiac failure); an occlusive central artery or vein (aorta, SVC, IVC); symptomatic pulmonary embolism. Consult haematology STAT and start anticoagulation as soon as possible — in life- or limb-threatening cases the attending neonatologist starts it with haematology guidance rather than waiting. For limb-threatening arterial thrombosis, contact surgery STAT.
Cerebral sinus venous thrombosis and thrombosis related to congenital heart disease sit outside this stratification. CSVT needs neurology and atrial or ventricular thrombi need cardiology, immediately.

Baseline studies, and the thrombophilia question

Before starting anticoagulation: CBC, PT, PTT, fibrinogen, antithrombin and D-dimer, plus a cranial ultrasound if the infant is at risk of IVH. Routine genetic thrombophilia testing in a neonate with thrombosis is controversial — in most cases the result will not change immediate management. The exceptions are the rare severe deficiencies of protein C, protein S and antithrombin, worth considering with a large thrombus burden or purpura fulminans. If an advanced workup is wanted, it is ordered as a three-step DVT panel; step 1 is the most useful at this age and should be sent first.

DVT 1 (1 blue top, 2.7 mL)	DVT 2 (1 red top, 3.0 mL)	DVT 3 (1 purple top, 1.0 mL)
Protein C, protein S, antithrombin, factor VIII, lupus anticoagulant	Anticardiolipin antibody, anti-β2-GP1, lipoprotein(a), homocysteine	Factor V Leiden, prothrombin gene mutation

Enoxaparin — treatment dose by postmenstrual age (Baylor Table 8-11)	Dose
PMA under 32 weeks	2 mg/kg/dose every 12 hours
PMA 32–40 weeks	1.7 mg/kg/dose every 12 hours
PMA over 40 weeks	1.5 mg/kg/dose every 12 hours
Prophylaxis, under 2 months	0.75 mg/kg/dose every 12 hours
Prophylaxis, over 2 months	0.5 mg/kg/dose every 12 hours
Rounding	Below 2.5 kg round to the nearest whole mg; above 2.5 kg round up to the nearest whole mg
Monitoring	Anti-Xa 4 hours after a dose, and only after at least 2 doses of a given regimen so the level reflects steady state. Treatment target 0.5–1, prophylaxis 0.2–0.4 units/mL. Once in range: next day, a week later, then every 1–4 weeks.

Duration, switching and stopping

Venous thromboembolism: 6 weeks to 3 months in total, with a repeat ultrasound before stopping to confirm resolution. If the thrombus was line-associated, prophylactic anticoagulation may continue until the line comes out.
Acute femoral artery thrombosis: at least 5–7 days of therapeutic anticoagulation.
UFH to enoxaparin: start enoxaparin within 1 hour of stopping the heparin infusion. Prophylactic enoxaparin to therapeutic UFH: start the infusion as soon as possible, with a load if clinically indicated. Therapeutic enoxaparin to therapeutic UFH: start the infusion 10–11 hours after the last enoxaparin dose, and do not load.
Before surgery or an invasive procedure: stop heparin 6 hours beforehand, enoxaparin at least 24 hours beforehand.
Removing a catheter with catheter-related thrombosis: the Chest guidelines suggest 3–5 days of anticoagulation before removal, but clinical judgement prevails.
UFH monitoring: heparin level and PTT 4 hours after the load and 4 hours after every rate change; once stable, every 12 hours, with platelets every 3 days. Note that the heparin assay is distorted by high plasma free haemoglobin, high bilirubin and low antithrombin — when the assay and the PTT disagree, check those before trusting the assay.

Heparin for line patency (Baylor Table 8-10) — heparin 1 unit/mL continuously	Weight <1250 g	Weight >1250 g
UAC	0.3 mL/h	0.5 mL/h
UVC	0.3 mL/h	0.5 mL/h
PICC	0.5 mL/h	0.5 mL/h
Peripheral arterial line	0.5 mL/h	0.5 mL/h

Scale of the problem

More than 80% of neonatal thromboembolic events are related to central venous or arterial catheters. Incidence is rising — about 6.8 per 1000 NICU admissions now, against 2.4 per 1000 in 1995. In a recent meta-analysis, catheter-related thrombosis occurred in 9.2% of cases (range 1.1–66.7%), and a fibrin sleeve forms within 2 days of insertion. Umbilical venous catheters typically cause asymptomatic transient thrombosis; portal vein thrombosis relates specifically to intrahepatic UVC placement and regresses spontaneously in most partial cases. Renal vein thrombosis presents mostly in males, usually left-sided, with the triad of haematuria, proteinuria and an abdominal mass — hypertension is a late finding.

9. Renal Vein Thrombosis

The Classic Non-Catheter Thrombosis

Triad: flank mass, macroscopic haematuria, and thrombocytopenia; risk factors include dehydration, polycythemia, sepsis, asphyxia, and infant of a diabetic mother.
Confirm with Doppler ultrasound; supportive care (hydration, treat the cause); anticoagulation is individualized per extent (unilateral vs bilateral/IVC extension) and bleeding risk with hematology.
Follow up renal function and blood pressure (risk of later hypertension/renal impairment/atrophy).

10. Monitoring

Parameter	When	Action
Serial Doppler ultrasound	To track thrombus	Detect resolution/propagation; adjust therapy.
Bleeding surveillance (cranial US)	Before/during anticoagulation	IVH risk — hold/adjust if bleeding.
Anticoagulant levels	On UFH/LMWH	Titrate per target (hematology).
Limb perfusion	Arterial thrombosis	Urgent if ischemic.
Renal function/BP	RVT follow-up	Detect late hypertension/impairment.

11. Precautions

Safety Cautions

Individualize anticoagulation — weigh thrombus threat against bleeding risk (IVH in preterm); involve hematology.
Screen for intracranial hemorrhage (cranial ultrasound) before anticoagulation in preterm infants.
Reserve thrombolysis for limb-/organ-/life-threatening thrombosis (major bleeding risk).
Treat arterial limb ischemia urgently.
Verify agents/doses/monitoring; do not routinely test for inherited thrombophilia (select cases only).

12. Escalation & Family Support

Family-Centered Communication

"Your baby has a blood clot, most often related to a drip line. We use scans to see it and carefully decide whether blood-thinning medicine is safe, because it can raise the risk of bleeding."
"Many small clots settle with monitoring; larger ones may need treatment. Our blood specialists help us choose the safest plan."

13. Key Pearls

High-Value Clinical Pearls

Neonates have the highest childhood thrombosis risk; most are catheter-related.
Doppler ultrasound is first-line; echo for intracardiac/great-vessel thrombus.
Renal vein thrombosis triad: flank mass + haematuria + thrombocytopenia.
Individualize anticoagulation vs bleeding risk (IVH); involve hematology; screen cranial US first in preterm.
Small/stable/asymptomatic thrombi are often monitored; thrombolysis only for limb-/organ-/life-threatening clots.
Treat arterial limb ischemia urgently; remove/replace thrombosed lines.

14. Common Mistakes to Avoid

Mistake	Why it harms	Better practice
Reflex anticoagulation.	IVH/bleeding.	Individualize; screen cranial US; hematology.
Missing arterial ischemia.	Limb loss.	Urgent assessment/treatment.
Ignoring line as source.	Propagation.	Assess/remove/replace lines.
Routine thrombophilia testing.	Low yield, misleading.	Test only selected cases.
No RVT follow-up.	Missed hypertension/renal loss.	Monitor renal function/BP.

15. Board-Style High-Yield Summary

Key Takeaways

Neonates have the highest childhood thrombosis incidence; most are catheter-related (UVC/UAC/central lines).
Renal vein thrombosis (commonest spontaneous): flank mass + haematuria + thrombocytopenia.
Confirm with Doppler ultrasound (echo for intracardiac/great-vessel).
Individualize anticoagulation vs bleeding risk (IVH); involve hematology; screen cranial ultrasound first in preterm infants.
Monitor small/stable clots; anticoagulate significant ones; reserve thrombolysis for limb-/organ-/life-threatening thrombosis.
Treat arterial limb ischemia urgently; assess/remove thrombosed lines; follow renal function/BP after RVT.

16. References

1.Monagle P, et al. (ASH). Venous thromboembolism in pediatric patients — guidelines. Blood Adv. 2018.
2.Monagle P, et al. (ACCP). Antithrombotic therapy in neonates and children. Chest.
3.West Midlands Neonatal ODN. Neonatal Thrombosis; Anticoagulation. Neonatal Guidelines 2025–28.
4.Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Ed. 33, 2025–2026.
5.Ministry of Health Belize. Neonatal Clinical Practice Guidelines 2018–2021.

Back to Clinical Guideline Hubs

Chapter 10.9 — Neonatal Thrombosis